CSLCSLLY -2.30%73 ROC (Joel Greenblatt) % is 7.34% as of Dec. 2025, which is 77% below its 10-year median of 32.31. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $48.70 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,326 Biotechnology companies, CSL ranks better than 80.39% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CSL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.34%.
The historical rank and industry rank for CSL's ROC (Joel Greenblatt) % or its related term are showing as below:
CSLLY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.63 Med: 32.31 Max: 44.1
Current: 3.63
During the past 13 years, CSL's highest ROC (Joel Greenblatt) % was 44.10%. The lowest was 3.63%. And the median was 32.31%.
CSLLY's ROC (Joel Greenblatt) % is ranked better than 80.39% of 1326
companies
in the Biotechnology industry
Industry Median: -297.95
vs CSLLY: 3.63
CSL's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -3.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for CSL's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, CSL's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CSL's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 7.34% mean?
CSL (CSLLY) has a ROC (Joel Greenblatt) % of 7.34% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CSL and its competitors. This is 77% below median its historical median of 32.31. Over the past decade, CSL's ROC (Joel Greenblatt) % has ranged from 3.63 to 44.10. According to the industry distribution chart, CSL ranks #260 out of 1326 companies in the Biotechnology industry, placing it in the top 19.6%.
Is CSL's ROC (Joel Greenblatt) % too high?
CSL's current ROC (Joel Greenblatt) % of 7.34% is 77% below median its 10-year median of 32.31. Over the past 10 years, this metric has ranged from a low of 3.63 to a high of 44.10. Based on the distribution chart, CSL ranks #260 out of 1326 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #260 out of 1326 companies for ROC (Joel Greenblatt) %. This places CSL in the top 20% of its industry — outperforming the majority of peers. Historically, CSL's own ROC (Joel Greenblatt) % has ranged from 3.63 to 44.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CSL and its competitors. CSL's current ROC (Joel Greenblatt) % is 7.34%, which is 77% below median its own 10-year median of 32.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.70, compared to a current price of $19.98 — trading 59% below its estimated fair value. The current ROC (Joel Greenblatt) % is 7.34%, which is 77% below median its 10-year median of 32.31. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CSL (CSLLY), the current ROC (Joel Greenblatt) % is 7.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $19.98 is trading 59% below its estimated GF Value™ of $48.70.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
ROC (Joel Greenblatt) %: 7.34% (77% below median its 10-year median of 32.31)
GF Value™: $48.70 vs. price of $19.98 (59% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
